RhumbLine Advisers’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

RhumbLine Advisers’s Portfolio ASLN Stock Details ASLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17	Hold	29	–	–	﹤0.01%	4080
2025 Q4	$17	Hold	29	–	–	﹤0.01%	4120
2025 Q3	$17	Sell	29 -72	-71%	-$42	﹤0.01%	4107
2025 Q2	$60	Sell	101 -59	-37%	-$35	﹤0.01%	4112
2025 Q1	$95	Hold	160	–	–	﹤0.01%	4100
2024 Q4	$95	Hold	160	–	–	﹤0.01%	4134
2024 Q3	$95	Sell	160 -2	-1%	-$4	﹤0.01%	4166
2024 Q2	$388	Hold	162	–	–	﹤0.01%	4298
2024 Q1	$794	Hold	162	–	–	﹤0.01%	4164
2023 Q4	$674	Hold	162	–	–	﹤0.01%	4183
2023 Q3	$2.39K	Hold	162	–	–	﹤0.01%	4092
2023 Q2	$4.72K	Buy	+162	New	+$5.01K	﹤0.01%	4099

RhumbLine Advisers's ASLN Position: Q1 2026 in Review

RhumbLine Advisers held its ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) position steady in Q1 2026 at 29 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #4080.

RhumbLine Advisers first reported a position in ASLN in Q2 2023 and has held it in 12 quarters since. The position peaked at $4.72K in Q2 2023. 1 fund tracked by Wall St. Rank holds ASLN as of Q1 2026.

RhumbLine Advisers held 29 shares of ASLAN Pharmaceuticals Limited American Depositary Shares worth $17 as of Q1 2026.
RhumbLine Advisers left its ASLAN Pharmaceuticals Limited American Depositary Shares share count unchanged in Q1 2026.
ASLAN Pharmaceuticals Limited American Depositary Shares made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #4080 holding.
RhumbLine Advisers first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q2 2023 and has held it in 12 quarters since.
RhumbLine Advisers's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $4.72K in Q2 2023.
1 fund tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.